Viemed Q2 Revenue Climbs 24% to $78.1M, but Higher Costs Weigh on Net Income; Medicare Overpayment Dispute Narrows to $2.2M
VMD sits 85% above its 52-week low of $5.93.
Summary
Viemed Healthcare reported Q2 2026 revenue of $78.1 million, up 24% year-over-year and matching consensus, but net income fell to $2.76 million. The company also disclosed a $2.2 million Medicare overpayment dispute following an unfavorable ALJ ruling.
Key Events · Earnings and Guidance · VMD
-
Q2 Revenue Up 24% to $78.1M
Revenue reached $78.1 million, driven by a record ventilator patient census of 12,635 and a near-doubling of equipment and supply sales to $19.0 million, largely from women's health products.
-
Net Income Declines 12% to $2.76M
Net income attributable to Viemed fell to $2.76 million from $3.16 million a year ago, as SG&A expenses grew 29% and a prior-year $0.6 million gain on equipment sales reversed to a $0.6 million loss.
-
Medicare Audit Overpayment Reduced to $2.2M, Unfavorable ALJ Ruling
The asserted overpayment from a Medicare audit was reduced from $5.9 million to $2.2 million on appeal, but an administrative law judge issued an unfavorable decision in June 2026. Viemed intends to pursue further appeals and has not accrued a loss.
-
Active Share Repurchases Continue
The company repurchased 680,802 shares for $6.5 million during the first half of 2026 under its new repurchase program, with 1.25 million shares remaining authorized.
Analysis · VMD · Industrial Applications And Services
Record Q2 revenue of $78.1 million—a 24% year-over-year increase—was fueled by growth in ventilator patients and women's health sales. Yet net income attributable to Viemed slipped 12% to $2.76 million, as selling, general and administrative expenses outpaced revenue growth and a prior-year gain on equipment sales did not recur. Adding to the mixed picture, an administrative law judge ruled unfavorably in the company's Medicare audit case, leaving a disputed overpayment of $2.2 million that Viemed plans to appeal further. While the top-line momentum and record patient census are encouraging, margin pressure and the unresolved regulatory matter cloud the quarter.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VMD was trading at $11.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $448.2M. The 52-week trading range was $5.93 to $12.61. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.